Tella Inc
TSE:2191
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| JP |
|
Tella Inc
TSE:2191
|
101.3m JPY |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
193.8B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
149.5B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
136.5T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
36B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
286.8B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
35.3B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28.3B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.6B USD |
Loading...
|
|
| CN |
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
164.3B HKD |
Loading...
|
Market Distribution
| Min | -179.8% |
| 30th Percentile | 21.8% |
| Median | 30.6% |
| 70th Percentile | 42.3% |
| Max | 18 197.9% |
Other Profitability Ratios
Tella Inc
Glance View
tella, Inc. engages in research and development of dendritic cell (DC) vaccine therapy. The company is headquartered in Shinjuku, Tokyo-To and currently employs 30 full-time employees. The company went IPO on 2009-03-26. The firm operates through three business segments. The Cell Medicine segment is engaged in the provision of cancer treatment technology and operational method centered on dendritic cell vaccine therapy. This segment is also engaged in the provision of Services for contract medical institutions, such as cell culture system maintenance support services, management system maintenance support services and disease support services. The Medical Support segment is mainly engaged in the provision of drug development services (CROs) and genetic testing services. The Pharmaceutical segment is engaged in the development of the dendritic cell vaccine for regulatory approval as a product for cancer regenerative medicine.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
Over the last 3 years, Tella Inc’s Gross Margin has decreased from 64.5% to -116.6%. During this period, it reached a low of -116.6% on Apr 3, 2022 and a high of 64.5% on Mar 31, 2019.
